The MGMT gene showed good prediction with regard to both sensitivity and resistance, which, is in contrast to results obtained by Codegoni and coworkers who failed to find any relation between MGMT expression, detected by northen blot analysis, and response to platinum-based therapy in patients with primary ovarian cancer [34]. This evidence concerns the gene MGMT and ovarian cancer.